Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Judith Leibovici, Orit Itzhaki, Monica Huszar & Judith Sinai. (2011) Targeting the Tumor Microenvironment by Immunotherapy: Part 2. Immunotherapy 3:11, pages 1385-1408.
Read now
Read now
Mark Pines. (2008) Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Expert Opinion on Drug Discovery 3:1, pages 11-20.
Read now
Read now
Articles from other publishers (26)
Bharti Singal & Jyoti Chhibber‐Goel. 2022. Drug Development for Malaria. Drug Development for Malaria
187
211
.
Harit Panda, Mikiko Suzuki, Mitsuru Naito, Ritsumi Saito, Huaichun Wen, Liam Baird, Akira Uruno, Kanjiro Miyata & Masayuki Yamamoto. (2022) Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. Free Radical Biology and Medicine 187, pages 92-104.
Crossref
Crossref
Dorothy Wavinya Nyamai & Özlem Tastan Bishop. (2020) Identification of Selective Novel Hits against Plasmodium falciparum Prolyl tRNA Synthetase Active Site and a Predicted Allosteric Site Using In Silico Approaches. International Journal of Molecular Sciences 21:11, pages 3803.
Crossref
Crossref
Carlo Follo, Chiara Vidoni, Federica Morani, Alessandra Ferraresi, Christian Seca & Ciro Isidoro. (2019) Amino acid response by Halofuginone in Cancer cells triggers autophagy through proteasome degradation of mTOR. Cell Communication and Signaling 17:1.
Crossref
Crossref
Paola Zigrino & Gerhard Sengle. (2019) Fibrillin microfibrils and proteases, key integrators of fibrotic pathways. Advanced Drug Delivery Reviews 146, pages 3-16.
Crossref
Crossref
Jacqueline Allen. (2016) Response of an ovine laryngeal injury model to a novel fibrosis inhibitor. ANZ Journal of Surgery 87:4, pages 266-270.
Crossref
Crossref
Kouhei Tsuchida, Tadayuki Tsujita, Makiko Hayashi, Asaka Ojima, Nadine Keleku-Lukwete, Fumiki Katsuoka, Akihito Otsuki, Haruhisa Kikuchi, Yoshiteru Oshima, Mikiko Suzuki & Masayuki Yamamoto. (2017) Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radical Biology and Medicine 103, pages 236-247.
Crossref
Crossref
Hisashi Oishi, Tereza Martinu, Masaaki Sato, Yasushi Matsuda, Shin Hirayama, Stephen C. Juvet, Zehong Guan, Tomohito Saito, Marcelo Cypel, David M. Hwang, Tracy L. Keller, Malcolm R. Whitman, Mingyao Liu & Shaf Keshavjee. (2016) Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model. The Journal of Heart and Lung Transplantation 35:4, pages 518-527.
Crossref
Crossref
Vitul Jain, Manickam Yogavel, Yoshiteru Oshima, Haruhisa Kikuchi, Bastien Touquet, Mohamed-Ali Hakimi & Amit Sharma. (2015) Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis. Structure 23:5, pages 819-829.
Crossref
Crossref
Vitul Jain, Haruhisa Kikuchi, Yoshiteru Oshima, Amit Sharma & Manickam Yogavel. (2014) Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase. Journal of Structural and Functional Genomics 15:4, pages 181-190.
Crossref
Crossref
Yan Song, Mingyi Zhang, Lina Zhao, Xiaohui Yin, Jiaohui Zhao, Juan Li, Rui He, Yanan Chang, Junjiang Jin, Yuliang Zhao, Jingyuan Li & Gengmei Xing. (2014) Regulation on mechanical properties of collagen: Enhanced bioactivities of metallofullerol. Nanomedicine: Nanotechnology, Biology and Medicine 10:4, pages 783-793.
Crossref
Crossref
Haruhisa Kikuchi, Seiko Horoiwa, Ryota Kasahara, Norimitsu Hariguchi, Makoto Matsumoto & Yoshiteru Oshima. (2014) Synthesis of febrifugine derivatives and development of an effective and safe tetrahydroquinazoline-type antimalarial. European Journal of Medicinal Chemistry 76, pages 10-19.
Crossref
Crossref
Noel P. McLaughlin, Paul Evans & Mark Pines. (2014) The chemistry and biology of febrifugine and halofuginone. Bioorganic & Medicinal Chemistry 22:7, pages 1993-2004.
Crossref
Crossref
Buvana Ravishankar & Tracy L. McGaha. (2013) O death where is thy sting? Immunologic tolerance to apoptotic self. Cellular and Molecular Life Sciences 70:19, pages 3571-3589.
Crossref
Crossref
Tracy L Keller, Davide Zocco, Mark S Sundrud, Margaret Hendrick, Maja Edenius, Jinah Yum, Yeon-Jin Kim, Hak-Kyo Lee, Joseph F Cortese, Dyann F Wirth, John David Dignam, Anjana Rao, Chang-Yeol Yeo, Ralph Mazitschek & Malcolm Whitman. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nature Chemical Biology 8:3, pages 311-317.
Crossref
Crossref
Yana G Kamberov, Jihoon Kim, Ralph Mazitschek, Winston P Kuo & Malcolm Whitman. (2011) Microarray profiling reveals the integrated stress response is activated by halofuginone in mammary epithelial cells. BMC Research Notes 4:1.
Crossref
Crossref
Vasiliki Kalliopi K. Bournia, Panayiotis G. Vlachoyiannopoulos, Carlo Selmi, Haralampos M. Moutsopoulos & M. Eric Gershwin. (2009) Recent Advances in the Treatment of Systemic Sclerosis. Clinical Reviews in Allergy & Immunology 36:2-3, pages 176-200.
Crossref
Crossref
Tatjana Barisic-Dujmovic, Ivana Boban, Douglas J. Adams & Stephen H. Clark. (2007) Marfan-Like Skeletal Phenotype in the Tight Skin (Tsk) Mouse. Calcified Tissue International 81:4, pages 305-315.
Crossref
Crossref
M. Leiba. (2006) Halofuginone inhibits NF- B and p38 MAPK in activated T cells. Journal of Leukocyte Biology 80:2, pages 399-406.
Crossref
Crossref
Thea D. TlstyLisa M. Coussens. (2006) TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT. Annual Review of Pathology: Mechanisms of Disease 1:1, pages 119-150.
Crossref
Crossref
Rashpal K. Bhogal, Cristina M. Stoica, Tracy L. McGaha & Constantin A. Bona. (2005) Molecular Aspects of Regulation of Collagen Gene Expression in Fibrosis. Journal of Clinical Immunology 25:6, pages 592-603.
Crossref
Crossref
Paul J Christner & Sergio A Jimenez. (2004) Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches. Current Opinion in Rheumatology 16:6, pages 746-752.
Crossref
Crossref
Sandhya Xavier, Ester Piek, Makiko Fujii, Delphine Javelaud, Alain Mauviel, Kathy C. Flanders, Ayelet M. Samuni, Angelina Felici, Michael Reiss, Shai Yarkoni, Anastasia Sowers, James B. Mitchell, Anita B. Roberts & Angelo Russo. (2004) Amelioration of Radiation-induced Fibrosis. Journal of Biological Chemistry 279:15, pages 15167-15176.
Crossref
Crossref
S. Sohail Ahmed & Filemon K. Tan. (2003) Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations. Current Opinion in Rheumatology 15:6, pages 766-771.
Crossref
Crossref
Léon C.L.T. van Kempen, Dirk J. Ruiter, Goos N.P. van Muijen & Lisa M. Coussens. (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. European Journal of Cell Biology 82:11, pages 539-548.
Crossref
Crossref
Mark Pines, David Snyder, Shai Yarkoni & Arnon Nagler. (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biology of Blood and Marrow Transplantation 9:7, pages 417-425.
Crossref
Crossref